AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+11.98%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$217M
AUM Growth
+$217M
(+19%)
Cap. Flow
+$29.3M
Cap. Flow
% of AUM
13.49%
Top 10 Holdings %
Top 10 Hldgs %
53.14%
Holding
73
New
14
Increased
11
Reduced
10
Closed
8
Top Buys
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
$12.9M |
| 2 |
Sanofi
SNY
|
$11.4M |
| 3 |
Ventyx Biosciences
VTYX
|
$5.94M |
| 4 |
PNT
POINT Biopharma Global Inc. Common Stock
PNT
|
$5.57M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
$4.99M |
Top Sells
Sector Composition
| 1 | Healthcare | 84.3% |
| 2 | Financials | 1.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
ARS Pharmaceuticals
SPRY
$1.08B
| – | – |
-170,000
| Closed | -$721K |
|
52
Repare Therapeutics
RPTX
$73.9M
| – | – |
-321,200
| Closed | -$4.49M |
|
53
Renovaro
RENB
$51.4M
| – | – |
0
| – | – |
|
54
Penumbra
PEN
$10.5B
| – | – |
0
| – | – |
|
55
Novavax
NVAX
$1.2B
| – | – |
0
| – | – |
|
56
Moderna
MRNA
$9.36B
| – | – |
0
| – | – |
|
57
Milestone Pharmaceuticals
MIST
$151M
| – | – |
0
| – | – |
|
58
Eli Lilly
LLY
$661B
| – | – |
0
| – | – |
|
59
Legend Biotech
LEGN
$6.64B
| – | – |
0
| – | – |
|
60
iShares Russell 2000 ETF
IWM
$66.6B
| – | – |
0
| – | – |
|
61
Iovance Biotherapeutics
IOVA
$800M
| – | – |
0
| – | – |
|
62
Geron
GERN
$893M
| – | – |
0
| – | – |
|
63
Invesco CurrencyShares Euro Currency Trust
FXE
$527M
| – | – |
0
| – | – |
|
64
Invesco CurrencyShares British Pound Sterling Trust
FXB
$90.4M
| – | – |
0
| – | – |
|
65
Fate Therapeutics
FATE
$115M
| – | – |
0
| – | – |
|
66
CRISPR Therapeutics
CRSP
$4.82B
| – | – |
0
| – | – |
|
67
Curis
CRIS
$21.5M
| – | – |
-340,349
| Closed | -$335K |
|
68
Celularity
CELU
$61.1M
| – | – |
0
| – | – |
|